- Home
- SWTX vs CLVT Comparison
SWTX vs CLVT Comparison
Compare SWTX & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- CLVT
- Stock Information
- Founded
- SWTX 2017
- CLVT 2016
- Country
- SWTX United States
- CLVT United Kingdom
- Employees
- SWTX N/A
- CLVT N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- CLVT EDP Services
- Sector
- SWTX Health Care
- CLVT Technology
- Exchange
- SWTX Nasdaq
- CLVT Nasdaq
- Market Cap
- SWTX 3.5B
- CLVT 2.8B
- IPO Year
- SWTX 2019
- CLVT N/A
- Fundamental
- Price
- SWTX $46.26
- CLVT $4.31
- Analyst Decision
- SWTX Buy
- CLVT Hold
- Analyst Count
- SWTX 7
- CLVT 4
- Target Price
- SWTX $56.86
- CLVT $5.83
- AVG Volume (30 Days)
- SWTX 8.7M
- CLVT 5.4M
- Earning Date
- SWTX 05-20-2025
- CLVT 04-29-2025
- Dividend Yield
- SWTX N/A
- CLVT N/A
- EPS Growth
- SWTX N/A
- CLVT N/A
- EPS
- SWTX N/A
- CLVT N/A
- Revenue
- SWTX $191,589,000.00
- CLVT $2,529,200,000.00
- Revenue This Year
- SWTX $86.36
- CLVT N/A
- Revenue Next Year
- SWTX $69.02
- CLVT $0.46
- P/E Ratio
- SWTX N/A
- CLVT N/A
- Revenue Growth
- SWTX 3417.33
- CLVT N/A
- 52 Week Low
- SWTX $28.21
- CLVT $3.04
- 52 Week High
- SWTX $62.00
- CLVT $7.30
- Technical
- Relative Strength Index (RSI)
- SWTX 58.93
- CLVT 61.54
- Support Level
- SWTX $46.10
- CLVT $4.13
- Resistance Level
- SWTX $46.27
- CLVT $4.41
- Average True Range (ATR)
- SWTX 0.90
- CLVT 0.19
- MACD
- SWTX 0.58
- CLVT 0.08
- Stochastic Oscillator
- SWTX 99.46
- CLVT 78.21
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.